According to the DREAMseq phase III clinical trial, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) (N/I), followed by the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) (D/T) if there was disease progression, led to a significant improvement in estimated 2-year overall survival from the start of treatment (72%) when compared to the opposite treatment sequence (52%).
In a phase Ib/II clinical trial known as EPCORE NHL-2, a team of researchers—led by Joshua Brody, director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai—showed the benefit of combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma. The results were published earlier this month in the journal Blood.
